Last reviewed · How we verify
Dyclone (DYCLONINE)
Dyclonine (DYCLONINE) is a small molecule drug that targets acetylcholinesterase. It is used to treat various conditions including itching of the skin, local anesthesia, minor skin wound pain, mouth irritation, and skin irritation. The current owner of Dyclonine is AstraZeneca, and it is off-patent with no active Orange Book patents. As a result, there is a generic manufacturer available. Dyclonine is used for its analgesic and anti-inflammatory properties.
At a glance
| Generic name | DYCLONINE |
|---|---|
| Sponsor | Astrazeneca |
| Drug class | dyclonine |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Itching of skin
- Local anesthesia
- Minor Skin Wound Pain
- Mouth Irritation
- Prevent Minor Bacterial Skin Infection
- Skin irritation
- Suppression of the Gag Reflex
Common side effects
Key clinical trials
- Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding (PHASE4)
- Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study (PHASE4)
- Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy (PHASE4)
- A Novel Portable Upper Gastrointestinal Endoscopy System (NA)
- Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |